PI3K: A rational target for ovarian cancer therapy?
Dent
Paul
P
Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, 23298-0035, USA. pdent@vcu.edu
Grant
Steven
S
Fisher
Paul B
PB
Curiel
David T
DT
D002470:Cell Survival; D004789:Enzyme Activation; D005260:Female; D006801:Humans; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics* / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D017978:Receptors, Growth Factor / Q000502:physiology; D015398:Signal Transduction
D017978:Receptors, Growth Factor; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase